Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gevokizumab - XOMA/Novartis

Drug Profile

Gevokizumab - XOMA/Novartis

Alternative Names: S-78989; VPM 087; XMA-005.2; XMA-0052; XOMA-052

Latest Information Update: 04 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XOMA
  • Developer IRIS; National Eye Institute; North Shore-Long Island Jewish Health System; Novartis; Servier; University of Zurich; XOMA
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Behcet's syndrome; Pyoderma; Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uveitis
  • Phase II Acne vulgaris; Acute coronary syndromes; Diabetic nephropathies; Giant cell arteritis; Labyrinthitis; Myositis; Osteoarthritis; Schnitzler syndrome; Scleritis
  • Phase I Colorectal cancer; Gastric cancer; Oesophageal cancer; Renal cell carcinoma
  • Suspended Rheumatoid arthritis
  • No development reported Cancer; Gout; Juvenile rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Pyoderma

Most Recent Events

  • 22 May 2019 Phase-I clinical trials in Colorectal cancer (Combination therapy, First-line therapy, Metastatic disease) in United Kingdom, Singapore, Japan (IV) (NCT03798626)
  • 22 May 2019 Phase-I clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Japan, Singapore, United Kingdom (IV) (NCT03798626)
  • 22 May 2019 Phase-I clinical trials in Gastric cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Japan, Singapore, United Kingdom (IV) (NCT03798626)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top